Anji Pharmaceuticals

Anji Pharmaceuticals is a privately held, Cambridge, MA-based biotechnology company founded in 2018 that focuses on drug discovery against high-value therapeutic targets validated by human genetics. It has raised approximately $105 million in venture funding across five rounds through 2021, with no disclosed products, customers, or commercial revenue.

Company typePrivate
Founded2018
HeadquartersCambridge, United States
Headcount1–10
GTM typeB2B
OfferingHardware or Manufacturing

Anji Pharmaceuticals firmographics

Firmographics

Name: Anji Pharmaceuticals
Website: https://anjipharma.com
Company type: Private
Founded year: 2018
Operating status: Operating
Headcount range: 1–10 employees
Short description: Anji Pharmaceuticals is a privately held, Cambridge, MA-based biotechnology company founded in 2018 that focuses on drug discovery against high-value therapeutic targets validated by human genetics. It has raised approximately $105 million in venture funding across five rounds through 2021, with no disclosed products, customers, or commercial revenue.
Ownership category
akta.pro rank

Anji Pharmaceuticals industry classification

Industry

Product category: Biopharmaceuticals
NAICS: Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC: Pharmaceutical Preparations (2834)
akta.pro primary industry: Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
akta.pro secondary industries: Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

Drug discovery
Human genetics
Biopharmaceutical development
Genetically validated targets
Targeted therapeutics

Where Anji Pharmaceuticals is headquartered

Location

Headquarters

HQ city: Cambridge
HQ country: United States
HQ region: North America

Markets served

Anji Pharmaceuticals business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Personnel, Technology or R&D, Operations

Anji Pharmaceuticals product offering

Product offering

Core offering

Anji Pharmaceuticals is a biopharmaceutical company that discovers and develops therapeutics against high-value disease targets validated by human genetics. The company focuses on translating genetic evidence into drug candidates aimed at clinically validated mechanisms.

Differentiator

Problem solved

Functional benefit

Companies that use Anji Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Anji Pharmaceuticals technology and API

Technology

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Anji Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators1 record

Anji Pharmaceuticals competitors and assessment

Company assessment

Direct peers

BridgeBio Pharma: A clinical-stage biotech built around genetically validated targets for serious diseases. Comparable to Anji in core thesis (human-genetics-driven drug discovery), though at substantially larger scale and with multiple approved/commercial assets.
Maze Therapeutics: A genetics-driven drug discovery company leveraging human genetic variation to identify and develop precision medicines. Closely comparable to Anji's stated strategy of tackling human-genetics-validated targets, at a similar early-to-mid-stage maturity.
CAMP4 Therapeutics: An early-stage biotech focused on regulatory RNA to address genetically validated disease drivers. Comparable to Anji as a venture-backed, genetics-anchored drug discovery platform with a similar funding profile.

Emerging players

Crinetics Pharmaceuticals: An endocrinology-focused biotech developing therapeutics for endocrine-related diseases including women's health indications. Comparable in therapeutic focus and similar stage profile to Anji's likely reproductive-health / endocrine programs.
Karuna Therapeutics: A CNS-focused biotech that advanced a genetically/neuroscience-validated mechanism to approval and was acquired by BMS. Relevant comparable for Anji's CNS programs given similar target-validation philosophy and similar-stage evolution.
Sage Therapeutics: A CNS-focused pharma developing genetically-informed therapies for brain health conditions. Comparable to Anji's CNS-leaning development path and small-molecule therapeutic modality.
Viridian Therapeutics: An endocrinology-focused clinical-stage biotech developing therapies for thyroid eye disease and other endocrine indications. Comparable to Anji's likely women's health/endocrine pipeline at a similar small-cap, venture-backed stage.

Broad incumbents

Regeneron Pharmaceuticals: A large-cap pharma with a foundational genetics-driven discovery platform (Regeneron Genetics Center). Represents the scaled-up, fully-realized version of Anji's human-genetics-validated thesis.
Ionis Pharmaceuticals: An established RNA-targeted therapeutics company with multiple approved products. Relevant for Anji's potential pipeline breadth across CNS and endocrine indications, though Ionis operates at vastly greater scale and modality specialization.
BioMarin Pharmaceutical: A rare-disease-focused commercial-stage biotech that built its pipeline around genetically validated targets. Illustrative of the genetic-validation thesis executed to commercial success — a useful comparable for what a successful Anji exit trajectory could look like.

Market position

Customer concentration

Anji Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anji Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Anji Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anji Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anji Pharmaceuticals

What does Anji Pharmaceuticals do?

When was Anji Pharmaceuticals founded?

Anji Pharmaceuticals was founded in 2018. It employs 1 to 10 people.

Where is Anji Pharmaceuticals based?

Anji Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

Who are Anji Pharmaceuticals's main competitors?

Direct peers on record are BridgeBio Pharma, Maze Therapeutics and CAMP4 Therapeutics. Emerging players are Crinetics Pharmaceuticals, Karuna Therapeutics, Sage Therapeutics and Viridian Therapeutics. Broad incumbents are Regeneron Pharmaceuticals, Ionis Pharmaceuticals and BioMarin Pharmaceutical.

Does Anji Pharmaceuticals have an API?

No public API is recorded for Anji Pharmaceuticals.

What industry is Anji Pharmaceuticals in?

Anji Pharmaceuticals's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.